Posted by Michael Wonder on 12 Jul 2023
Enhertu approved in China as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer
12 July 2023 - Approval based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reduced the risk of disease progression or death by 50% and increased median overall survival by more than 6 months vs. chemotherapy.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
